GlaxoSmithKline (NYSE:GSK) is working with a Japanese biotechnology company to see if that company’s technology can find potential new cancer treatments. GSK’s agreement with Tokyo-based Chiome Bioscience calls for the companies to first conduct a pilot study using Chiome’s proprietary technology. Chiome’s proprietary platform technology can generate antibodies. Under the agreement, GSK and Chiome will generate monoclonal antibodies, antibodies that can seek out and recognize cancers anywhere in the body. Depending on how the pilot goes, GSK has the option to pursue further development. No financial terms were disclosed.
